EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activities of the Novel Bacterial Topoisomerase Inhibitor OSUAB-0284 against the Biothreat Pathogen Bacillus anthracis and Its Type II Topoisomerases

Chelsea A Mann iD, Stephanie A Halasohoris, Annette M Gray, Jennifer Chua, Jade L Spencer, Bobby J Curry, Ashley L Babyak, Christopher P Klimko, Christopher K Cote, Jason S West, Mark J Mitton-Fry iD, J Matthew Meinig iD und 1 weitere

ACS Infectious Diseases · 2026

DOI: 10.1021/acsinfecdis.5c00860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2026. Verfasst von Chelsea A Mann und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States. Hauptthemen laut MEDLINE: Bacillus anthracis, Anti-Bacterial Agents, Topoisomerase II Inhibitors, DNA Topoisomerases, Type II. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, Division of Microbiology and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bacillus anthracisAnti-Bacterial AgentsTopoisomerase II InhibitorsDNA Topoisomerases, Type IITopoisomerase InhibitorsAnimalsAnthraxMicrobial Sensitivity TestsDNA GyraseCiprofloxacinRabbits

Stichwörter der Autor:innen

Bacillus anthracisOSUAB-0284anthraxgepotidacingyrasetopoisomerase IV

Substanzen

Anti-Bacterial AgentsTopoisomerase II InhibitorsDNA GyraseCiprofloxacinDNA Topoisomerases, Type IITopoisomerase Inhibitors

Autor:innen und Institutionen

  • Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
  • Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, Fort Detrick, Maryland 21702, United States.
  • Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University College of Pharmacy, Columbus, Ohio 43210, United States.
  • Departments of Biochemistry and Medicine (Hematology/Oncology), Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.

ORCID-Profile: Chelsea A Mann, Mark J Mitton-Fry, J Matthew Meinig, Neil Osheroff

Förderung

  • NIAID NIH HHS
  • NIGMS NIH HHS
  • Division of Microbiology and Infectious Diseases
  • Defense Threat Reduction Agency
  • National Institute of General Medical Sciences
  • JobsOhio Early-Stage Technology Fund

Zitieren

APA

Mann, C. A., Halasohoris, S. A., Gray, A. M., Chua, J., Spencer, J. L., Curry, B. J., Babyak, A. L., Klimko, C. P., Cote, C. K., West, J. S., Mitton-Fry, M. J., Meinig, J. M., & Osheroff, N. (2026). Activities of the Novel Bacterial Topoisomerase Inhibitor OSUAB-0284 against the Biothreat Pathogen Bacillus anthracis and Its Type II Topoisomerases. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.5c00860

Vancouver

Mann CA, Halasohoris SA, Gray AM, Chua J, Spencer JL, Curry BJ, et al. Activities of the Novel Bacterial Topoisomerase Inhibitor OSUAB-0284 against the Biothreat Pathogen Bacillus anthracis and Its Type II Topoisomerases. ACS Infectious Diseases. 2026. doi:10.1021/acsinfecdis.5c00860

BibTeX
@article{Mann2026,
  author = {Mann, Chelsea A and Halasohoris, Stephanie A and Gray, Annette M and Chua, Jennifer and Spencer, Jade L and Curry, Bobby J and Babyak, Ashley L and Klimko, Christopher P and Cote, Christopher K and West, Jason S and Mitton-Fry, Mark J and Meinig, J Matthew and Osheroff, Neil},
  title = {Activities of the Novel Bacterial Topoisomerase Inhibitor OSUAB-0284 against the Biothreat Pathogen Bacillus anthracis and Its Type II Topoisomerases},
  journal = {ACS Infectious Diseases},
  year = {2026},
  doi = {10.1021/acsinfecdis.5c00860}
}
Kostenlos starten →